加味葛根芩连汤结合肛塞清肠栓治疗溃疡性结肠炎的效果观察

[目的]观察加味葛根芩连汤联合肛塞清肠栓治疗溃疡性结肠炎的临床疗效.[方法]120例轻中度溃疡性结肠炎患者被随机分为:口服加味葛根芩连汤联合肛塞清肠栓组(L组)、口服加味葛根芩连汤组(G组)、肛塞清肠栓组(Q组)、口服柳氮磺胺吡啶组(S组),每组30例.观察比较各组患者治疗前后症状总积分、黏液脓血便、里急后重等单项症状积分及肠镜下表现积分的变化.[结果]L组能有效改善患者总体症状和肠镜检查所见的病理表现,且优于其他3组疗法,总有效率为96.67％;在改善”里急后重”和”黏液脓血便”症状方面,也较其他3组疗法起效更快.[结论]加味葛根芩连汤联合肛塞清肠栓能有效改善溃疡性结肠炎患者的总体症状和肠镜下病理表现.     

基于网络药理学探究葛根芩连汤异病同治的机制研究

目的 本文通过探究葛根芩连汤“一方治三病”的作用机制,“三病”即溃疡性结肠炎、肠易激综合征和2型糖尿病,从实际范例中寻找中医药异病同治理论的应用证据。方法 采用网络药理学方法,通过中药系统药理学数据库(Traditional Chinese medicine systems pharmacology database, TCMSP)获取葛根芩连汤的主要活性成分及作用靶点,利用Gene cards、TTD、OMIM数据库获取溃疡性结肠炎、肠易激综合征和2型糖尿病3种疾病的相关靶点。将以上获得的4组靶点取交集获取共同靶点,利用Cytoscape软件绘制“葛根芩连汤-有效成分-共有靶点”网络图;结合STRING数据库绘制PPI网络图,再导入Cytoscape软件进行拓扑分析及可视化。运用Metascape数据库对共有靶点进行基因本体(Gene Ontology, GO)富集分析和京都基因与基因组百科全书(Kyoto encylopedia of genes and genomes, KEGG)通路富集分析。结果 筛选并得到葛根芩连汤异病同治溃疡性结肠炎、肠易激综合征、2型糖尿病的共同作用靶点...     

基于网络药理学探讨白头翁汤治疗溃疡性结肠炎的作用机制

[目的]运用网络药理学方法分析白头翁汤治疗溃疡性结肠炎(UC)的潜在作用机制,以期为白头翁汤的进一步研究及UC的新药研发提供参考。[方法]运用中医药生物信息学分析工具(BATMAN-TCM)筛选白头翁汤中有效成分作用靶点,通过TTD、Drugbank、Uniprot、DisGeNET数据库收集UC相关的靶点,使用R软件筛选出共同靶点,采用Cytoscape3.6.1软件构建中药-成分-疾病靶点网络,进一步采用cytoHubba构建蛋白互作(PPI)核心网络,最后通过DAVID进行基因本体(GO)功能富集分析和基于京都基因与基因组百科全书(KEGG)通路富集分析研究其作用机制。[结果]白头翁汤中共有42个有效成分,对应靶点655个,与UC疾病靶标映射后获得85个共同靶点,主要富集在50个生物过程和36条信号通路。[结论]白头翁汤可能通过VDR、BAX、TNF、NR3C1、ESR1、ADRA2A、SLC6A4、GPBAR1、HTR3A等多个靶点调控TLRs、NF-κB、NLRs、5-HT、AA等多个通路,进而对消化系统、内分泌系统、免疫系统等多系统进行干预,协同抑制UC引起的炎症损伤。     

葛根芩连汤治疗糖尿病患者效果分析

目的分析葛根芩连汤对糖尿病患者的治疗效果。方法研究年度2015年1—10月,对象糖尿病74例,经随机法分组。37例治疗选用常规疗法,入组对照组;在该基础上,给予余37例葛根芩连汤,入组实验组。对比疗效。结果对照组的证候积分[治疗前积分(28.53±7.02)分,治疗后(17.33±6.28)分]、治疗有效率(83.78%)、血糖指标和实验组相比较,实验组证候积分下降明显[治疗前积分(28.59±7.21)分,治疗后(10.24±5.42)分],治疗有效率高(94.59%),血糖指标下降幅度大。组间相比差异有统计学意义(P0.05)。结论葛根芩连汤治疗糖尿病效果佳,血糖改善明显,可推广应用。     

加味葛根芩连汤治疗婴幼儿腹泻106例

婴幼儿腹泻是儿科常见病和多发病。常规治疗主要是控制饮食、补液、抗感染和对症处理。 1 992年1 1月～ 2 0 0 0年 2月 ,我们对常规治疗效果欠佳以及自愿服用中药的患儿 ,应用加味葛根芩连汤治疗 ,取得较好疗效 ,现报告如下。1　资料与方法1 .1　临床资料 :共治疗腹泻患儿 1 1 6例 ,其中记录完整的病例 1 0 6例 ,均符合文献 [1 ]诊断标准。男 5 8例 ,女 48例 ;年龄 4个月～ 2岁 ;轻型 70例 ,重型 36例 ;大便水样或蛋花样 64例 ,粘液绿色稀水便 42例 ;轻度脱水 5 3例 ,中度脱水 1 4例 ;合并上呼吸道感染 5 2例 ,佝偻病 2例 ,营养不良 2例。检…     

基于Keap1/Nrf2信号通路探讨葛根芩连汤治疗溃疡性结肠炎小鼠肠黏膜损伤机制

目的 基于氧化应激信号通路探讨葛根芩连汤抗溃疡性结肠炎的作用机制。方法 50只BALB/C雄性小鼠随机分为正常组、模型组、葛根芩连汤低、高剂量、柳氮磺吡啶组。除正常组外,其他各组自由饮用2.5%葡聚糖硫酸钠,连续7 d,造模成功后给予药物连续干预7 d。每天记录小鼠体质量、粪便等一般生理状态;比较结肠长度;苏木素-伊红(HE)染色观察结肠组织形态学变化;酶联免疫吸附试验(ELISA)检测血清白细胞介素(IL)-1β、IL-6、肿瘤坏死因子(TNF)-α的含量。Western印迹检测结肠组织核因子-E2相关因子(Nrf)2、Kelch-样ECH相关蛋白(Keap)1、细胞外调节蛋白激酶(ERK)1/2蛋白表达水平。结果 与模型组相比,葛根芩连汤各剂量组体质量下降趋势明显得到缓解,且腹泻、便血症状得到改善;血清中IL-1β、IL-6、TNF-α的含量明显降低(P<0.01);HE染色发现结肠组织病理性损伤明显减轻;Western印迹结果显示,葛根芩连汤各剂量组结肠组织中Keap1蛋白表达量明显降低,Nrf2、p-ERK1/2蛋白表达明显升高(P<0.05)。结论 葛根芩连汤通过...     

葛根芩连汤化载治疗溃疡结肠炎（湿热型）32例疗效观察

溃疡性结肠炎(简称溃结)病因未明,一般认为与炎症介质,免疫损伤、遗传因素等有关,病变主要局限于结、直肠的粘膜,表现为炎证、充血水肿、糜烂或溃疡,常以腹痛,腹泻、脓血便或血便特征,中医把它归属于泄泻、痢疾、腹痛、肠风等的范畴。笔在96～98年间使用葛根芩连汤加味治疗湿热型溃结病人32例,取得了较好的效果。现报告如下：     

葛根芩连汤灌肠治疗婴幼儿轮状病毒性肠炎80例

目的为探求治疗小儿病毒性肠炎的有效治疗方法。方法 :取《伤寒论》中葛根芩连汤为主方 ,水煎后取汁保留灌肠 ,每日 1次。结果 :治疗 80例 ,患儿腹泻得到控制 ,总有效率 95 %。结论 :葛根芩连汤保留灌肠 ,为临床治疗小儿病毒性肠炎行之有效的治疗措施。该法操作简单 ,疗效确切 ,家长及患儿易于接受。     

葛根芩连汤结合瑞格列奈片用于2型糖尿病治疗的效果评价

目的 针对2型糖尿病的治疗,采用葛根芩连汤结合瑞格列奈片的用药方式,基于临床实践评价控糖效果。方法 本研究患者所取时段为2020年1月—2021年12月,共计纳入浦城县中医医院收治的60例2型糖尿病患者依据患者自愿的方式加以分组,单一组（30例）采用瑞格列奈片治疗,联合组（30例）采用葛根芩连汤结合瑞格列奈片治疗。对比两种方法控糖效果结果 用药干预后,联合组有效率为90.00%,与单一组的66.67%相比更体现出效果,差异有统计学意义（P<0.05）。治疗前,两组患者血糖指标各项内容对比,差异无统计学意义（P>0.05）;治疗后,联合组各项指标均优于单一组,差异有统计学意义（P<0.05）。治疗前,两组中医证候各项评分比较,差异无统计学意义（P>0.05）;经过治疗,两组症状均有改善,但是联合组优于单一组,差异有统计学意义（P<0.05）。治疗前,两组胰岛功能指标,差异无统计学意义（P>0.05）;经过治疗,观察HOMA-β水平要高于单一组,同时FINS、HOMA-IR要低于单一组,差异有统计学意义（P<0.05）。用药治疗期间联合组不良反应要...     

化瘀通络汤对大鼠实验性溃疡性结肠炎血小板活化的影响

[目的]观察化瘀通络汤对大鼠实验性溃疡性结肠炎（UC）的疗效和对其血小板活化的影响，探讨化瘀通络汤治疗UC的机制及UC的发病机制。[方法]将动物按体重随机分为化瘀通络组、柳氮磺胺吡啶（SASP）组、模型对照组和正常对照组。其中除正常对照组外其余3组均采用2，4-二硝基氯苯和醋酸复合法制作UC大鼠模型。各组连续治疗4周后，取外周血测血清P-选择素和可溶性CD40配体（sCD40L）的水平。[结果]模型对照组血清P-选择素和sCD40L水平及肠黏膜损伤评分较正常对照组、化瘀通络组和SASP组显著升高（P〈0．05），而化瘀通络组与SASP组间差异无统计学意义（P〉0．05）。[结论]血小板活化在UC发病过程中起重要作用。化瘀通络汤治疗UC有效，其机制可能在于对血小板活化的阻抑而间接对免疫炎症进行调解，也可能直接通过对免疫炎症反应的调解而实现。     

Systems pharmacology approach reveals protective mechanisms of Jian-Pi Qing-Chang decoction on ulcerative colitis

BACKGROUND Given the complex pathogenesis of ulcerative colitis (UC), the conventional therapeutic methods are not fully curative. As a sort of systematic complementary and alternative medicine, traditional Chinese medicine (TCM) provides new options for the standard therapy. Nevertheless, there are still numerous problems with the promotion of TCM attributed to its complexity, and consequently, new research approaches are urgently needed. Thus, we explored the protective effects of Jian-Pi Qing-Chang (JPQC) decoction on UC based on systems pharmacology approach, which might fill the current innovation gap in drug discovery and clinical practice pertaining to TCM. AIM To investigate the protective mechanisms of JPQC decoction on UC based on systems pharmacology approach. METHODS We performed systems pharmacology to predict the active ingredients, the matched targets, and the potential pharmacological mechanism of JPQC on UC. In vivo, we explored the effects of JPQC in a colitis model induced by dextran sulfate sodium. In vitro, we adopted the bone marrow-derived macrophages (BMDMs) as well as BMDMs co-cultured with Caco2 cells to verify the underlying mechanisms and effects of JPQC on UC under TNF-α stimulation. RESULTS Systems pharmacology revealed 170 targets for the 107 active ingredients of JPQC and 112 candidate targets of UC. Protein-protein interaction networks were established to identify the underlying therapeutic targets of JPQC on UC. Based on enrichment analyses, we proposed our hypothesis that JPQC might have a protective effect on UC via the NF-κB/HIF-1α signalling pathway. Subsequent experimental validation revealed that treatment with TNFα activated the NF-κB/HIF-1α signalling pathway in BMDMs, thereby damaging the epithelial barrier permeability in co-cultured Caco2 cells, while JPQC rescued this situation. The findings were also confirmed in a dextran sulfate sodium-induced colitis model. CONCLUSION JPQC could improve the mucosal inflammatory response and intestinal epithelial barrier function via the NF-κB/HIF-1α signalling pathway, which provides new perspectives on the pharmaceutical development and clinical practice of TCM.     

Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients via gut microbiota

BACKGROUNDWe previously showed, using the Traditional Chinese Medicine System Pharmacology Database, that Gegen Qinlian decoction (GQD) had a direct antitumor effect, and was combined with programmed cell death protein (PD)-1 inhibitors to treat microsatellite stable (MSS) tumor-bearing mice. However, the effect of GQD on patients with colorectal cancer (CRC) is not clear.AIMTo determine the therapeutic mechanism of GQD in improving immune function, reducing inflammation and protecting intestinal barrier function.METHODSSeventy patients with CRC were included in this study: 37 in the control group and 33 in the treatment group. The proportions of CD4⁺ T, CD8⁺ T, natural killer (NK), NKT and T regulatory cells were measured by flow cytometry. Levels of the cytokines tumor necrosis factor (TNF)-α, interferon (IFN)-γ, interleukin (IL)-2, IL-6, IL-10 and serotonin (5-hydroxytryptamine; 5-HT) in serum were assessed by enzyme-linked immunosorbent assay (ELISA). The expression of zonula occludens (ZO)-1, occludin, nuclear factor (NF)-κB and TNF-α in tumor and normal tissues was measured by immunohistochemistry. The composition of gut microbiota from patients in the treatment group was assessed using 16S rDNA analysis. RESULTSThere were no adverse events in the treatment group. The proportion of CD4⁺ T cells and NKT cells in the post-treatment group was significantly higher than that in the pre-treatment and control groups (P < 0.05). The level of TNF-α in the post-treatment group was significantly lower than that in the pre-treatment and control groups (P < 0.05). The concentration of 5-HT in the post-treatment group was significantly lower than that in the pre-treatment group (P < 0.05). The expression of ZO-1 and occludin in tumor tissues in the treatment group was significantly higher than that in the control group (P < 0.05). The expression of ZO-1 in normal tissues of the treatment group was significantly higher than that in the control group (P = 0.010). Compared with the control group, expression of NF-κB and TNF-α in tumor tissues of the treatment group was significantly decreased (P < 0.05). Compared with the pre-treatment group, GQD decreased the relative abundance of Megamonas and Veillonella. In addition, GQD increased the relative abundance of Bacteroides, Akkermansia and Prevotella. CONCLUSIONGQD enhances immunity and protects intestinal barrier function in patients with CRC by regulating the composition of gut microbiota.     

基于网络药理学探讨附子理中汤治疗非酒精性脂肪性肝病作用机制

目的:运用网络药理学方法分析附子理中汤(FZLZD)治疗非酒精性脂肪肝性病(NAFLD)的潜在作用机制。方法:检索TCMSP数据库筛选出FZLZD药物活性成分及作用靶点,并借助Uniprot平台进行靶点蛋白规范化处理。检索GeneCards与OMIM数据库得到NAFLD靶点基因,进一步获取药物和疾病共有靶点,即为FZLZD治疗NAFLD的潜在靶点基因。利用Cytoscape 3.7.2绘制药物活性成分-靶点-疾病网络图,利用Cytoscape 3.7.2结合String数据库构建蛋白互作(PPI)网络,利用Metascape数据库对共有靶点进行GO和KEGG富集分析。结果:最终筛选出80种药物活性成分、43个潜在作用靶点;富集分析获取808个生物学过程及25条与NAFLD相关信号通路。结论:FZLZD通过多成分-多靶点-多信号通路协同调控NAFLD。     

新加白头翁汤治疗活动期溃疡性结肠炎的临床疗效评价

目的:观察新加白头翁汤联合西药对比单用西药治疗溃疡性结肠炎(UC)的临床疗效.方法:采用前瞻性队列研究.纳入活动期UC患者50例,对照组24例,试验组26例.试验组予新加白头翁汤联合西药治疗,对照组单用西药治疗,观察临床疗效.结果:与对照组比较,试验组临床缓解率69.2％高于对照组37.5％(P＜0.05);临床有效率...     

Study on the mechanism of warming yang and reducing turbidity decoction in the treatment of diabetic kidney disease based on network pharmacology

This study aimed to investigate the mechanism of warming yang and reducing turbidity decoction in the treatment of diabetic kidney disease (DKD) by network pharmacology. The active components and corresponding targets of warming yang and reducing turbidity decoction were screened through the Traditional Chinese Medicine Systems Pharmacology database, DKD-related targets were obtained from Genecard and Online Mendelian Inheritance in Man databases, and drug-disease common targets were screened through Venny online website. Then we used STRING and Cytoscape software to analyze and perform protein–protein interaction network, and used CytoNCA plug-in to perform topological analysis to screen out the core target. We used RStudio to performed gene ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. One hundred one active components in warming yang and reducing turbidity decoction participated in the regulation of the body’s response to foreign bodies, lipopolysaccharides, metal ions, ketone bodies, hypoxia and oxidative stress by regulating 186 targets related to DKD, and played a role in the treatment of DKD by interfering with pathways such as interfered with lipids and atherosclerosis, PI3K-Akt, fluid shear stress and atherosclerosis, AGE-RAGE and cell senescence. It was implied that warming yang and reducing turbidity decoction had the features of multi components, multi targets and multi pathways in the treatment of DKD, which might create methods and directions for further verification of the molecular mechanism of warming yang and reducing turbidity decoction.     

肠愈宁治疗活动期溃疡性结肠炎疗效观察

[目的]观察肠愈宁颗粒治疗活动期溃疡性结肠炎(UC)的临床疗效.[方法]60例患者随机分为2组各30例,治疗组予以中药肠愈宁颗粒口服,10g,早晚分服;对照组予口服美沙拉嗪1.0 g/次,4次/d.8周为1个疗程.观察2组患者治疗后主要临床症状、结肠镜下黏膜改善情况及临床疗效.[结果]治疗组总有效率为93.3％,对照组90.0％,2组比较差异无统计学意义(P＞0.05).临床症状改善情况2组比较差异亦无统计学意义(P＞0.05).[结论]肠愈宁颗粒治疗活动期UC疗效显著,与西药美沙拉嗪相当,值得临床推广应用.